Optimization of aerosol deposition by pressure support in children with cystic fibrosis: an experimental and clinical study.
Nebulized aerosols are commonly used to deliver drugs into the lungs of patients with cystic fibrosis (CF). The aim of this study was to assess the effectiveness of pressure-support (PS) ventilation in increasing aerosol deposition within the lungs of children with CF. An in vitro study demonstrated the feasibility of coupling a breath-actuated nebulizer to a PS device. An in vivo study was done with 18 children (ages 6 to 21 yr) with clinically stable CF, each of whom underwent both a standard and a PS-driven ventilation scan (control session and PS session, respectively). In addition, a perfusion scan was used to determine lung outlines and to construct a geometric model for quantifying aerosol deposition by radioactivity counting in MBq. Homogeneity of nebulization was evaluated from the four first-order moments of aerosol distribution in the peripheral and central lung regions. The time-activity nebulization curve was linear in all patients, with higher slopes during the PS than during the control session (0.43 +/- 0.07 [mean +/- SD] MBq/min and 0.32 +/- 0.23 MBq/min, respectively; p < 0.018). Quantitatively, aerosol deposition was about 30% greater after the PS session (4.4 +/- 2.7 MBq) than after the control session (3.4 +/- 2.1 MBq; p < 0.05). Similarly, deposition efficacy (as a percentage of nebulizer output) was significantly better during the PS session than during the control session (15.3 +/- 8.3% versus 11.5 +/- 5.7%, p < 0.05). No differences in the regional deposition pattern or in homogeneity of uptake were observed. In conclusion, our data show that driving the delivery of a nebulized aerosol by noninvasive PS ventilation enhances total lung aerosol deposition without increasing particle impaction in the proximal airways.
Fauroux
B
B
Department of Pediatric Pulmonology, Armand Trousseau Hospital, Air Liquide Santé International, Paris, France. bfauroux@aol.com
Itti
E
E
Pigeot
J
J
Isabey
D
D
Meignan
M
M
Ferry
G
G
Lofaso
F
F
Willemot
J M
JM
Clément
A
A
Harf
A
A
D000293:Adolescent; D000336:Aerosols; D002648:Child; D003131:Combined Modality Therapy; D003550:Cystic Fibrosis / Q000000981:diagnostic imaging / Q000628:therapy*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D016014:Linear Models; D008168:Lung / Q000000981:diagnostic imaging; D008297:Male; D009330:Nebulizers and Vaporizers / Q000706:statistics & numerical data; D015609:Organotechnetium Compounds; D010833:Phytic Acid; D011175:Positive-Pressure Respiration / Q000295:instrumentation* / Q000706:statistics & numerical data; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D013668:Technetium Tc 99m Aggregated Albumin; D012122:Ventilators, Mechanical
D000336:Aerosols; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D013668:Technetium Tc 99m Aggregated Albumin; C026177:technetium phytate; D010833:Phytic Acid